gastroparesis with tirzepatide Lawsuit - Ozempic, Wegovy & Mounjaro GLP-1 Manufacturers Argue Gastroparesis Lawsuits
Description
[4] [5] These effects may vary by population, dose, and baseline characteristics
While early evidence suggests that dual receptor modulators may offer enhanced metabolic control and potentially greater kidney protection compared to standard GLP-1RAs, further research is needed to establish conclusive outcomes and determine their role in the therapeutic landscape for CKD management
Vildagliptin attenuates Huntingtons disease through activation of GLP-1 Receptor/PI3K/Akt/BDNF pathway in 3-Nitropropionic acid rat model
doi:10.1016/j.eclinm.2023.102162
